Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations. (3rd March 2019)
- Record Type:
- Journal Article
- Title:
- Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations. (3rd March 2019)
- Main Title:
- Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations
- Authors:
- Winiarska, Aleksandra
Zareba, Lech
Krolczyk, Grzegorz
Czyzewicz, Grzegorz
Zabczyk, Michal
Undas, Anetta - Other Names:
- Tacke Frank Academic Editor.
- Abstract:
- Abstract : Background . Histidine-rich glycoprotein (HRG) displays anticoagulant and antifibrinolytic properties in animal models, but its effects in humans are unclear. We investigated serum HRG levels and their associations with the disease stage and prothrombotic alterations in lung cancer (LC) patients. Methods . In 148 patients with advanced LC prior to anticancer therapy (87 non-small-cell LC and 61 small-cell LC) versus 100 well-matched controls, we measured HRG levels in association with clot permeability (K s ), clot turbidimetry (lag phase and maximum absorbance), and clot lysis time (CLT). Results . Compared to controls, LC patients had 45.9% lower HRG levels with no associations with demographics and comorbidities. Decreased HRG, defined as the 90 th percentile of control values (<52.7 μ g/ml), was 16 times more common in subjects with than without LC (OR = 16.4, 95% CI 9.2-23.5, p < 0.01 ).HRG < 38 μ g/ml discriminated stage IIIAB/limited disease from IV/extensive disease (ED) LC. In LC patients, HRG correlated inversely with CLT (r = − 0.41, p < 0.001 ), but not with other fibrin variables. Among stage IV/ED LC, HRG correlated significantly withK s and lag phase (r = 0.28 andr = 0.33, respectively, bothp < 0.001 ). LC patients with lowK s (10 th percentile of control values) combined with prolonged CLT (90 th percentile of control values) had reduced HRG levels compared to the remainder (p = 0.003 ). No such observations were noted in controls. Conclusions .Abstract : Background . Histidine-rich glycoprotein (HRG) displays anticoagulant and antifibrinolytic properties in animal models, but its effects in humans are unclear. We investigated serum HRG levels and their associations with the disease stage and prothrombotic alterations in lung cancer (LC) patients. Methods . In 148 patients with advanced LC prior to anticancer therapy (87 non-small-cell LC and 61 small-cell LC) versus 100 well-matched controls, we measured HRG levels in association with clot permeability (K s ), clot turbidimetry (lag phase and maximum absorbance), and clot lysis time (CLT). Results . Compared to controls, LC patients had 45.9% lower HRG levels with no associations with demographics and comorbidities. Decreased HRG, defined as the 90 th percentile of control values (<52.7 μ g/ml), was 16 times more common in subjects with than without LC (OR = 16.4, 95% CI 9.2-23.5, p < 0.01 ).HRG < 38 μ g/ml discriminated stage IIIAB/limited disease from IV/extensive disease (ED) LC. In LC patients, HRG correlated inversely with CLT (r = − 0.41, p < 0.001 ), but not with other fibrin variables. Among stage IV/ED LC, HRG correlated significantly withK s and lag phase (r = 0.28 andr = 0.33, respectively, bothp < 0.001 ). LC patients with lowK s (10 th percentile of control values) combined with prolonged CLT (90 th percentile of control values) had reduced HRG levels compared to the remainder (p = 0.003 ). No such observations were noted in controls. Conclusions . Our study is the first to show that decreased HRG levels occur in advanced LC and are associated with the disease stage and hypofibrinolysis. … (more)
- Is Part Of:
- Disease markers. Volume 2019(2019)
- Journal:
- Disease markers
- Issue:
- Volume 2019(2019)
- Issue Display:
- Volume 2019, Issue 2019 (2019)
- Year:
- 2019
- Volume:
- 2019
- Issue:
- 2019
- Issue Sort Value:
- 2019-2019-2019-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-03-03
- Subjects:
- Diagnosis -- Periodicals
Biochemical markers -- Periodicals
Pathology -- Periodicals
616 - Journal URLs:
- https://www.hindawi.com/journals/dm/ ↗
- DOI:
- 10.1155/2019/8170759 ↗
- Languages:
- English
- ISSNs:
- 0278-0240
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 10620.xml